(Q41726923)

English

Phase I/II study of paclitaxel, carboplatin, and methotrexate in advanced transitional cell carcinoma: a well-tolerated regimen with activity independent of p53 mutation

scientific article published on April 2000

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

8 October 2017

Phase I/II study of paclitaxel, carboplatin, and methotrexate in advanced transitional cell carcinoma: a well-tolerated regimen with activity independent of p53 mutation (English)

1 reference

Europe PubMed Central

8 October 2017

transitional cell carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Edelman MJ

1

1 reference

Europe PubMed Central

8 October 2017

Meyers FJ

2

1 reference

Europe PubMed Central

8 October 2017

Miller TR

3

1 reference

Europe PubMed Central

8 October 2017

Williams SG

4

1 reference

Europe PubMed Central

8 October 2017

Gandour-Edwards R

5

1 reference

Europe PubMed Central

8 October 2017

deVere White RW

6

1 reference

Europe PubMed Central

8 October 2017

language of work or name

0 references

publication date

1 April 2000

1 reference

Europe PubMed Central

8 October 2017

1 reference

Europe PubMed Central

8 October 2017

55

1 reference

Europe PubMed Central

8 October 2017

521-525

1 reference

Europe PubMed Central

8 October 2017

4

1 reference

Europe PubMed Central

8 October 2017

Cancer statistics, 1999.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900538-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900538-5

7 January 2021

based on heuristic

inferred from DOI database lookup

M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900538-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A carboplatin-based regimen for the treatment of patients with advanced transitional cell carcinoma of the urothelium

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900538-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900538-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900538-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900538-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900538-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Correlation of genetic and immunodetection of TP53 mutations in malignant and benign prostate tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900538-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900538-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Paclitaxel, cisplatin and methotrexate combination chemotherapy is active in the treatment of refractory urothelial malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900538-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900538-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900538-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: a phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900538-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900538-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Accumulation of nuclear p53 and tumor progression in bladder cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900538-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Methotrexate resistance in human uroepithelial cells with p53 alterations

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900538-5

7 January 2021

based on heuristic

inferred from DOI database lookup

p53 and treatment of bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900538-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Absence of p53 overexpression and favorable response to cisplatin-based neoadjuvant chemotherapy in urothelial carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900538-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0090-4295(99)00538-5

1 reference

Europe PubMed Central

8 October 2017

1 reference

Europe PubMed Central

8 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41726923&oldid=1926616583"